[ad_1]
FedEx Express, a subsidiary of New York Stock Exchange-listed FedEx, announced the FedEx Life Sciences Center in Mumbai, setting a benchmark for clinical trial supply chains in India and globally.
According to an official release, this new capability will meet and support clinical trial storage and logistics requirements for both medical customers within the Indian market and those shipping to India from around the world. “This facility ensures compliance with the quality and regulatory requirements of the healthcare industry.”
The main features of the new center are:
*Covering all three temperature control zones
*Controlled ambient temperature (15°C to 25°C)
*Refrigerated (2°C to 8°C)
*Frozen -20℃, frozen -80℃
* 24/7 monitoring and alarms for immediate response and intervention
*Disposal service for returned investigational medicinal products (IMPs)
*Equipped with secure archive facility with document storage and firewall
*Quality management system complies with Good Clinical Practice (GCP) and Good Distribution Practice (GDP).and
*We use gel packs and dry ice to ensure reliable packaging and replenishment.
Nitin Navneet Tatiwala, vice president of marketing for FedEx Express Middle East, Indian Subcontinent and Africa, said: Fulfills all clinical trial storage and distribution requirements for Indian healthcare customers. This new center will be in addition to FedEx’s current LSCs in Japan, South Korea, Singapore, the United States and the Netherlands, creating a global network of storage and distribution locations to support the company’s medical and pharmaceutical customers. . ”
Customers can utilize FedEx Customized Freight (FCF) to transport critical pharmaceutical shipments and choose FedEx Priority Alert Plus to monitor time-sensitive shipments, the release added.
[ad_2]
Source link
